YishengBio

YS Biopharma Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of vaccines and biologics for infectious diseases and cancer. The company's history traces back to 2002 when founder Yi Zhang initiated its vaccine business in the People's Republic of China (PRC). A key entity, Liaoning Yisheng Biopharmaceutical Co. Ltd., was originally founded in 1994 as Liaoning Biological Technology Company and was later renamed in 2005. The group expanded its operations internationally to the United States and Singapore starting in 2009.

The company's business model centers on generating revenue from its commercialized products while advancing a pipeline of new candidates. Its primary revenue stream comes from the YSJA™ rabies vaccine, which is a leading product in China. Since its production launch in 2020, over 19.9 million doses have been sold to more than 1,687 county-level Centers for Disease Control and Prevention (CDCs) in China as of March 2023. The company operates on a global scale, with a corporate structure that includes a holding company in the Cayman Islands and subsidiaries in China, the U.S., Singapore, and the Philippines. In March 2023, YS Biopharma went public on the Nasdaq through a merger with Summit Healthcare Acquisition Corp., a special purpose acquisition company (SPAC), which was expected to provide approximately $36 million in gross proceeds to fund clinical development and commercialization.

At the core of its research and development is the proprietary PIKA® immunomodulating technology platform. This platform utilizes a synthetic dsRNA complex that activates the immune system through TLR3, RIG-I, and MDA-5 signaling pathways to induce a prompt production of interferons and cytokines. This technology forms the basis for a new generation of vaccines and therapeutics designed to offer improved treatments for viral infections and cancer. The product pipeline includes several clinical-stage candidates, such as the PIKA rabies vaccine, which aims to provide faster protection with a one-week regimen compared to the conventional three or four-week schedules. Other candidates in development target Hepatitis B, COVID-19, and various cancers.

Keywords: YS Biopharma, YishengBio, biopharmaceutical, vaccine development, infectious diseases, cancer therapeutics, PIKA technology, rabies vaccine, immunology, clinical trials, Nasdaq: YS, Yi Zhang, biologics manufacturing, immunotherapy, adjuvant technology, YSJA, viral infections, oncology, Summit Healthcare Acquisition Corp., global biopharma, TLR3 agonist